Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
出版年份 2018 全文链接
标题
Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
作者
关键词
-
出版物
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
Volume 19, Issue S1, Pages 31-39
出版商
Springer Nature America, Inc
发表日期
2018-10-30
DOI
10.1007/s40257-018-0384-3
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Topical Timolol for Paronychia and Pseudopyogenic Granuloma in Patients Treated With Epidermal Growth Factor Receptor Inhibitors and Capecitabine
- (2018) Xavier Cubiró et al. JAMA Dermatology
- Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer
- (2018) Azael Freites-Martinez et al. JAMA Dermatology
- A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash
- (2017) Viswanath R. Belum et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings
- (2017) V. Sibaud et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial
- (2017) Hope S Rugo et al. LANCET ONCOLOGY
- Pigmentations de la muqueuse buccale
- (2017) Jean-Christophe Fricain et al. PRESSE MEDICALE
- Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors
- (2017) Emmanuelle Vigarios et al. SUPPORTIVE CARE IN CANCER
- Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors
- (2017) Sarah Bétrian et al. JAMA Dermatology
- A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer
- (2016) M. E. Lacouture et al. ANNALS OF ONCOLOGY
- Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy
- (2016) H. S. Rugo et al. ANNALS OF ONCOLOGY
- Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
- (2016) Vincent Sibaud et al. CURRENT OPINION IN ONCOLOGY
- Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
- (2016) V.R. Belum et al. EUROPEAN JOURNAL OF CANCER
- BRAF inhibitor therapy–associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression
- (2016) Kumaran Mudaliar et al. HUMAN PATHOLOGY
- Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy
- (2016) Kurt B. Schaberg et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Nivolumab therapy before vemurafenib administration induces a severe skin rash
- (2016) K. Imafuku et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Anti-PD1-induced psoriasis: a study of 21 patients
- (2016) J. Bonigen et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Dermoscopic Evaluation of Melanocytic Nevi Changes With Combined Mitogen-Activated Protein Kinase Pathway Inhibitors Therapy for Melanoma
- (2016) Marie Perier-Muzet et al. JAMA Dermatology
- Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia
- (2016) Carole Bitar et al. JAMA Dermatology
- Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy
- (2016) Veronica J. Shi et al. JAMA Dermatology
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
- (2016) Camille Hua et al. JAMA Dermatology
- Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1
- (2016) J. Naidoo et al. Cancer Immunology Research
- Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up
- (2015) D. E. Peterson et al. ANNALS OF ONCOLOGY
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors
- (2015) E. Vigarios et al. BRITISH JOURNAL OF DERMATOLOGY
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
- (2015) M. Freeman-Keller et al. CLINICAL CANCER RESEARCH
- Erfolgreiche Medikamentendesensibilisierung nach Vemurafenib-induziertem Arzneimittelexanthem
- (2015) N. Klossowski et al. HAUTARZT
- RASopathic alopecia: Hair changes associated with vemurafenib therapy
- (2015) Bianca Maria Piraccini et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Nail toxicities induced by systemic anticancer treatments
- (2015) Caroline Robert et al. LANCET ONCOLOGY
- Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma
- (2015) Giuliana Carlos et al. JAMA Dermatology
- Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
- (2015) Martina Sanlorenzo et al. JAMA Dermatology
- Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy
- (2015) Jennifer A. Lo et al. JAMA Oncology
- Toxicité endobuccale des thérapies ciblées anticancéreuses
- (2014) V. Sibaud et al. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE
- Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients
- (2014) Viswanath Reddy Belum et al. CANCER
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of Dermatologic Adverse Events on Quality of Life in 283 Cancer Patients: A Questionnaire Study in a Dermatology Referral Clinic
- (2013) Alyx C. Rosen et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
- (2013) P. A. Ott et al. CLINICAL CANCER RESEARCH
- Melanoma Patients under Vemurafenib: Prospective Follow-Up of Melanocytic Lesions by Digital Dermoscopy
- (2013) Marie Perier-Muzet et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Hair Follicle Mesenchyme-Associated PD-L1 Regulates T-Cell Activation Induced Apoptosis: A Potential Mechanism of Immune Privilege
- (2013) Xiaojie Wang et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non-small cell lung cancer
- (2013) Yoshio Kiyohara et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis
- (2013) Courtney J. Ensslin et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Geographic Tongue Induced by Angiogenesis Inhibitors
- (2013) T. Hubiche et al. ONCOLOGIST
- Alopecia With Endocrine Therapies in Patients With Cancer
- (2013) V. Saggar et al. ONCOLOGIST
- Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma
- (2013) M. E. Lacouture et al. ONCOLOGIST
- Epidermal EGFR Controls Cutaneous Host Defense and Prevents Inflammation
- (2013) B. M. Lichtenberger et al. Science Translational Medicine
- Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis
- (2012) Aaron M. Drucker et al. BREAST CANCER RESEARCH AND TREATMENT
- Hair shaft abnormalities after chemotherapy and tamoxifen therapy in patients with breast cancer evaluated by optical coherence tomography
- (2012) J. Lindner et al. BRITISH JOURNAL OF DERMATOLOGY
- Risk of Rash in Cancer Patients Treated with Vandetanib: Systematic Review and Meta-Analysis
- (2012) Alyx C. Rosen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Vemurafenib Sensitivity Skin Reaction after Ipilimumab
- (2012) James J. Harding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- Induction of Cutaneous Squamous Cell Carcinomas by RAF Inhibitors: Cause for Concern?
- (2011) Mario E. Lacouture et al. JOURNAL OF CLINICAL ONCOLOGY
- The risk of nail changes with epidermal growth factor receptor inhibitors: A systematic review of the literature and meta-analysis
- (2011) Benjamin C. Garden et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Periungual and subungual pyogenic granuloma
- (2010) B.M. Piraccini et al. BRITISH JOURNAL OF DERMATOLOGY
- Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients
- (2010) B. Nardone et al. CLINICAL CANCER RESEARCH
- Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer
- (2010) Mario E. Lacouture et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Treatment of Epidermal Growth Factor Receptor Antagonist-Induced Skin Rash: Results of a Survey among German Oncologists
- (2010) Jessica C. Hassel et al. ONKOLOGIE
- Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors
- (2009) A. Osio et al. BRITISH JOURNAL OF DERMATOLOGY
- Dermatologic Infections in Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitor Therapy
- (2009) R. E. Eilers et al. JNCI-Journal of the National Cancer Institute
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started